ACIP has approved the use of PEDIARIX™ for the Vaccine for Children program and recommends that, in addition to FDA-approved uses, 3 doses of PEDIARIX™ can be administered to an infant who is born to a woman who is hepatitis B surface antigen (HBsAg)-positive or whose HBsAg status is unknown. ACIP also approved a minimum interval of 4 weeks between the first and second doses when used in an accelerated vaccination schedule; the third dose should not be given before age 24 weeks.

  • Recommendation
  • Americas
  • United States of America
  • Diphtheria